Annual EBITDA
-$54.46 M
+$119.11 M+68.63%
31 December 2023
Summary:
Standard BioTools annual earnings before interest, taxes, depreciation & amortization is currently -$54.46 million, with the most recent change of +$119.11 million (+68.63%) on 31 December 2023. During the last 3 years, it has fallen by -$19.85 million (-57.37%). LAB annual EBITDA is now -302.76% below its all-time high of -$13.52 million, reached on 01 December 2010.LAB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$20.44 M
+$17.69 M+46.40%
30 September 2024
Summary:
Standard BioTools quarterly earnings before interest, taxes, depreciation & amortization is currently -$20.44 million, with the most recent change of +$17.69 million (+46.40%) on 30 September 2024. Over the past year, it has dropped by -$6.92 million (-51.16%). LAB quarterly EBITDA is now -1368.39% below its all-time high of -$1.39 million, reached on 01 September 2020.LAB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$109.71 M
-$6.92 M-6.73%
30 September 2024
Summary:
Standard BioTools TTM earnings before interest, taxes, depreciation & amortization is currently -$109.71 million, with the most recent change of -$6.92 million (-6.73%) on 30 September 2024. Over the past year, it has dropped by -$56.89 million (-107.69%). LAB TTM EBITDA is now -5323.18% below its all-time high of -$2.02 million, reached on 01 December 2009.LAB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LAB EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +68.6% | -51.2% | -107.7% |
| 3 y3 years | -57.4% | -96.1% | -114.6% |
| 5 y5 years | -75.9% | -163.2% | -135.3% |
LAB EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -57.4% | +68.6% | -286.5% | +71.6% | -147.8% | +36.8% |
| 5 y | 5 years | -75.9% | +68.6% | -1368.4% | +71.6% | -262.9% | +36.8% |
| alltime | all time | -302.8% | +68.6% | -1368.4% | +71.6% | -5323.2% | +36.8% |
Standard BioTools EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.44 M(-46.4%) | -$109.71 M(+6.7%) |
| June 2024 | - | -$38.13 M(+13.7%) | -$102.79 M(+34.9%) |
| Mar 2024 | - | -$33.54 M(+90.6%) | -$76.22 M(+40.0%) |
| Dec 2023 | -$54.46 M(-68.6%) | -$17.60 M(+30.1%) | -$54.46 M(+3.1%) |
| Sept 2023 | - | -$13.52 M(+17.0%) | -$52.83 M(-18.5%) |
| June 2023 | - | -$11.56 M(-1.9%) | -$64.79 M(-42.9%) |
| Mar 2023 | - | -$11.78 M(-26.2%) | -$113.49 M(-34.6%) |
| Dec 2022 | -$173.57 M(+292.1%) | -$15.97 M(-37.4%) | -$173.57 M(+6.6%) |
| Sept 2022 | - | -$25.49 M(-57.7%) | -$162.89 M(+10.2%) |
| June 2022 | - | -$60.26 M(-16.2%) | -$147.83 M(+47.2%) |
| Mar 2022 | - | -$71.86 M(+1258.9%) | -$100.44 M(+126.9%) |
| Dec 2021 | -$44.27 M(+27.9%) | -$5.29 M(-49.3%) | -$44.27 M(-13.4%) |
| Sept 2021 | - | -$10.43 M(-19.0%) | -$51.12 M(+21.5%) |
| June 2021 | - | -$12.87 M(-18.0%) | -$42.09 M(+9.1%) |
| Mar 2021 | - | -$15.69 M(+29.2%) | -$38.59 M(+11.5%) |
| Dec 2020 | -$34.60 M(-25.8%) | - | - |
| Dec 2020 | - | -$12.14 M(+772.3%) | -$34.60 M(+14.5%) |
| Sept 2020 | - | -$1.39 M(-85.1%) | -$30.23 M(-21.5%) |
| June 2020 | - | -$9.37 M(-19.9%) | -$38.52 M(-2.7%) |
| Mar 2020 | - | -$11.70 M(+50.6%) | -$39.59 M(-15.1%) |
| Dec 2019 | -$46.62 M(+50.6%) | - | - |
| Dec 2019 | - | -$7.77 M(-19.7%) | -$46.62 M(+1.9%) |
| Sept 2019 | - | -$9.68 M(-7.3%) | -$45.75 M(+5.0%) |
| June 2019 | - | -$10.45 M(-44.2%) | -$43.59 M(+4.0%) |
| Mar 2019 | - | -$18.73 M(+171.6%) | -$41.93 M(+35.4%) |
| Dec 2018 | -$30.95 M(-21.4%) | -$6.90 M(-8.3%) | -$30.95 M(+9.2%) |
| Sept 2018 | - | -$7.52 M(-14.4%) | -$28.35 M(-10.7%) |
| June 2018 | - | -$8.78 M(+13.2%) | -$31.76 M(-7.5%) |
| Mar 2018 | - | -$7.76 M(+80.8%) | -$34.35 M(-12.7%) |
| Dec 2017 | -$39.37 M | -$4.29 M(-60.8%) | -$39.37 M(-19.4%) |
| Sept 2017 | - | -$10.93 M(-3.8%) | -$48.85 M(-6.1%) |
| June 2017 | - | -$11.37 M(-11.0%) | -$52.03 M(-4.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$12.78 M(-7.2%) | -$54.37 M(-3.6%) |
| Dec 2016 | -$56.42 M(+71.7%) | -$13.77 M(-2.5%) | -$56.42 M(+11.5%) |
| Sept 2016 | - | -$14.12 M(+3.0%) | -$50.60 M(+24.6%) |
| June 2016 | - | -$13.71 M(-7.6%) | -$40.61 M(+10.6%) |
| Mar 2016 | - | -$14.83 M(+86.6%) | -$36.71 M(+11.7%) |
| Dec 2015 | -$32.87 M(-14.6%) | -$7.95 M(+92.4%) | -$32.87 M(+4.8%) |
| Sept 2015 | - | -$4.13 M(-57.9%) | -$31.36 M(-13.9%) |
| June 2015 | - | -$9.81 M(-10.7%) | -$36.41 M(+3.2%) |
| Mar 2015 | - | -$10.98 M(+70.5%) | -$35.27 M(-8.4%) |
| Dec 2014 | -$38.50 M(+178.5%) | -$6.44 M(-29.8%) | -$38.50 M(+7.1%) |
| Sept 2014 | - | -$9.17 M(+5.8%) | -$35.96 M(+18.4%) |
| June 2014 | - | -$8.67 M(-39.0%) | -$30.37 M(+20.9%) |
| Mar 2014 | - | -$14.21 M(+264.5%) | -$25.12 M(+81.7%) |
| Dec 2013 | -$13.82 M(-14.0%) | -$3.90 M(+8.7%) | -$13.82 M(+7.3%) |
| Sept 2013 | - | -$3.59 M(+4.9%) | -$12.88 M(+1.1%) |
| June 2013 | - | -$3.42 M(+17.2%) | -$12.75 M(-3.0%) |
| Mar 2013 | - | -$2.92 M(-1.3%) | -$13.14 M(-18.2%) |
| Dec 2012 | -$16.07 M(-9.7%) | -$2.96 M(-14.3%) | -$16.07 M(+3.7%) |
| Sept 2012 | - | -$3.45 M(-9.5%) | -$15.49 M(-2.1%) |
| June 2012 | - | -$3.81 M(-34.8%) | -$15.82 M(-13.9%) |
| Mar 2012 | - | -$5.85 M(+146.1%) | -$18.38 M(+3.3%) |
| Dec 2011 | -$17.79 M(+31.6%) | -$2.38 M(-37.1%) | -$17.79 M(-1.2%) |
| Sept 2011 | - | -$3.78 M(-40.7%) | -$18.02 M(+8.8%) |
| June 2011 | - | -$6.37 M(+21.0%) | -$16.56 M(+17.6%) |
| Mar 2011 | - | -$5.27 M(+102.7%) | -$14.08 M(+4.3%) |
| Dec 2010 | -$13.52 M(-5.9%) | -$2.60 M(+12.0%) | -$13.50 M(+4.5%) |
| Sept 2010 | - | -$2.32 M(-40.4%) | -$12.92 M(+21.9%) |
| June 2010 | - | -$3.90 M(-16.8%) | -$10.60 M(+58.1%) |
| Mar 2010 | - | -$4.68 M(+131.4%) | -$6.70 M(+231.4%) |
| Dec 2009 | -$14.36 M(-44.0%) | -$2.02 M | -$2.02 M |
| Dec 2008 | -$25.65 M(+25.6%) | - | - |
| Dec 2007 | -$20.42 M(+2.9%) | - | - |
| Dec 2006 | -$19.83 M | - | - |
FAQ
- What is Standard BioTools annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Standard BioTools?
- What is Standard BioTools annual EBITDA year-on-year change?
- What is Standard BioTools quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Standard BioTools?
- What is Standard BioTools quarterly EBITDA year-on-year change?
- What is Standard BioTools TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Standard BioTools?
- What is Standard BioTools TTM EBITDA year-on-year change?
What is Standard BioTools annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of LAB is -$54.46 M
What is the all time high annual EBITDA for Standard BioTools?
Standard BioTools all-time high annual earnings before interest, taxes, depreciation & amortization is -$13.52 M
What is Standard BioTools annual EBITDA year-on-year change?
Over the past year, LAB annual earnings before interest, taxes, depreciation & amortization has changed by +$119.11 M (+68.63%)
What is Standard BioTools quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of LAB is -$20.44 M
What is the all time high quarterly EBITDA for Standard BioTools?
Standard BioTools all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$1.39 M
What is Standard BioTools quarterly EBITDA year-on-year change?
Over the past year, LAB quarterly earnings before interest, taxes, depreciation & amortization has changed by -$6.92 M (-51.16%)
What is Standard BioTools TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of LAB is -$109.71 M
What is the all time high TTM EBITDA for Standard BioTools?
Standard BioTools all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.02 M
What is Standard BioTools TTM EBITDA year-on-year change?
Over the past year, LAB TTM earnings before interest, taxes, depreciation & amortization has changed by -$56.89 M (-107.69%)